Mycobacterial infections caused by nontuberculous mycobacteria

Seminars in Respiratory and Critical Care Medicine

Volumn 25, Issue 3, 2004, Pages 283-295

  Heifets, Leonid ^a,b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Environmental mycobacteria; Infections with opportunistic mycobacteria; Mycobacterium; Nontuberculous mycobacteria (NTM)

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; CAPREOMYCIN; CEFOXITIN; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; CYCLOSERINE; DOXYCYCLINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; IMIPENEM; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; QUINOLONE DERIVATIVE; RIFABUTIN; RIFAMPICIN; SULFONAMIDE; TETRACYCLINE; TIGECYCLINE; TOBRAMYCIN;

AEROSOL; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIAL TRANSMISSION; BACTERIOLOGY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE PREDISPOSITION; ENVIRONMENT; HUMAN; IMMUNITY; INFECTION SENSITIVITY; INSTRUMENT; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; MYCOBACTERIUM; MYCOBACTERIUM AVIUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NONTUBERCULOUS MYCOBACTERIUM; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOIL; WATER CONTAMINATION;

EID: 3042731112     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-829501     Document Type: Review

References (91)

1. Amfah G, Bonsu F, Tetteh C, et al. Buruli ulcer in Ghana: results of a national case search. Emerg Infect Dis 2002;8: 167-170
2. Van der Wert T, Stinear T, Stienstra Y, Vander Graaf WTA, Small PL. Mycobactones and Mycobacterium ulcerans disease. Lancet 2003;362:1062-1064
3. Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 1979;119:107-159
4. Wayne LG, Sramek HA. Agents of newly recognized or infrequently encountered mycobacterial diseases. Clin Microbiol Rev 1992;5:1-25
5. Goodfellow M, Wayne LG. Taxonomy and nomenclature. In: Ratledge C, Stanford J, eds. The Biology of the Mycobacteria, Vol 1. London: Academic; 1982:471-521
6. Woods GL, Washington JA. Mycobacteria other than Mycobacterium tuberculosis: review of microbiologic and clinical aspects. Rev Infect Dis 1987;9:275-294
7. Goodfellow M, Magee JG. Taxonomy of mycobacteria. In: Gangadharam PRJ, Jenkins PA, eds. Mycobacteria, Vol. I: Basic Aspects. New York: Chapman and Hall (International Thomson Publishing); 1998:1-71
8. Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of 1990s. Clin Microbiol Rev 2003;16:319-354
9. Sneath PHA. International Code of Nomenclature of Bacteria. Washington DC: American Society for Microbiology; 1992
10. Wallace RJ, Glassroth J, Griffith DE, Oliver KN, Cook JL, Gordin F. Diagnosis and treatment of disease caused by nontuberculous mycobacteria (American Thoracic Society Statement). Am J Respir Crit Care Med 1997;156:1-25
11. Good RC, Snider DE. Isolation of nontuberculous mycobacteria in the United States. J Infect Dis 1982;146:829-833
12. Kent PT, Kubica GP. Public Health Mycobacteriology (a guide for the level III laboratory). Atlanta: Centers for Disease Control; 1985
13. Witebsky FG, Kruczak-Filipov P. Identification of mycobacteria by conventional methods. In: Heifets LB, ed. Clinical Mycobacteriology. Philadelphia: WB Saunders; 1996:569-602 Clinics in Laboratory Medicine, Vol 16
14. Heifets LB, Jenkins PA. Speciation of mycobacteria in clinical laboratories. In: Gangadharam PRJ, Jenkins PA, eds. Mycobacteria, Vol. I: Basic Aspects. New York: Chapman and Hall (International Thompson Publishing); 1998:308-350
15. Rogall T, Flohr T, Böttger EC. Differentiation of Mycobacterium species by direct sequencing of amplified DNA. J Gen Microbiol 1990;136:1915-1920
16. Butler WR, Jost KC, Kilburn JO. Identification of mycobacteria by high-performance liquid chromatography. J Clin Microbiol 1991;29:2468-2472
17. Kirschner P, Springer B, Vogel U. Genotypic identification of mycobacteria by nucleic acid sequence determination: report of a two year experience in a clinical laboratory. J Clin Microbiol 1993;31:2882-2889
18. Thibert L, Lapierre S. Routine application of high-performance liquid chromatography for identification of mycobacteria. J Clin Microbiol 1993;31:1759-1763
19. Glickman SE, Kilburn SO, Butler WR. Rapid identification of mycolic acid patterns of mycobacteria by high-performance liquid chromatography using pattern recognition software and a Mycobacterium library. J Clin Microbiol 1994;32:740-749
20. Roberts GD, Böttger EC, Stockman L. Methods for the rapid identification of mycobacterial species. In: Heifets LB, eds. Clinical Mycobacteriology. Philadelphia: WB Saunders; 1996:603-639 Clinics in Laboratory Medicine, Vol 16
21. El Amin NM, Hanson HS, Pettersson B, Petrini B, Von Stedink LV. Identification of nontuberculous mycobacteria: 16S rRNA gene sequense analysis vs. conventional methods. Scand J Infect Dis 2000;32:47-50
22. Butler WR, Guthertz LS. Mycolic acid analysis by high-performance liquid chromatography for identification of Mycobacterium species. Clin Microbiol Rev 2001;14:704-726
23. Claud JL, Neal J, Rosenberry R, et al. Identification of Mycobacterium spp. by using a commercial 16S ribosomal DNA sequencing kit and additional sequencing libraries. J Clin Microbiol 2002;40:400-406
24. Hall L, Doerr KA, Wohlfiel SL, Roberts GD. Evaluation of the MicroSeq system for identification of mycobacteria by 16S ribisomal DNA sequencing and its integration into routine clinical mycobacteriology laboratory. J Clin Microbiol 2003; 41:1447-1453
25. Eisenach KD, Sifford MD, Cave MD, Bates JH, Crawford JT. Detection of Mycobacterium tuberculosis in sputum samples using polymerase chain reaction. Am Rev Respir Dis 1991; 144:1160-1163
26. Forbes BA, Hicks KES. Direct detection of Mycobacterium tuberculosis in respiratory specimens in a clinical laboratory by polymerase chain reaction. J Clin Microbiol 1993;31:1688-1694
27. Shinnick TM, Jonas V. Molecular approach to the diagnosis of tuberculosis. In: Bloom BR, ed. Tuberculosis: Pathogenesis, Protection, and Control. Washington, DC: ASM; 1994: 517-530
28. Pfyffer GE, Kissling P, Wirth R, Weber R. Direct detection of Mycobacterium tuberculosis complex in respiratory specimens by a target-amplified test system. J Clin Microbiol 1994;32: 918-923
29. Desmond E, Loretz K. Use of the Gen-Probe amplified Mycobacterium Tuberculosis Direct Test for early detection of Mycobacterium tuberculosis in BACTEC 12B medium. J Clin Microbiol 2001;39:1993-1995
30. Jost KC Jr, Dunbar DF, Barth SS, Headley VL, Elliot LB. Identification of Mycobacterium tuberculosis and M. avium complex directly from smear-positive sputum specimens and Bactec 12B cultures by high-performance liquid chromatography with fluorescence detection and computer-driven pattern recognition models. J Clin Microbiol 1995;33:1270-1277
31. Wolinsky E, Rynearson TK. Mycobacteria in soil and their relation to disease-associated strains. Am Rev Respir Dis 1968;97:1031-1037
32. Portaels F. Epidemiology of mycobacterial diseases. Clin Dermatol 1995;13:297:207-222
33. Falkinham JO. Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev 1996;9:177-215
34. Falkinham JO. Nontuberculous mycobacteria in the environment. In: Catanzaro A, Daley CL, eds. Lung Disease Due to Nontuberculous Mycobacterial Infections. Philadelphia: WB Saunders; 2003:520-553 Clinics in Chest Medicine, Vol 23
35. Marras TK, Daley CL. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. In: Catanzaro A, Daley CL, eds. Lung Disease Due to Nontuberculous Mycobacterisl Infections. Philadelphia: WB Saunders; 2003:553-568 Clinics in Chest Medicine, Vol 23
36. Iseman MD, Buschman DL, Ackerson LM. Pectus excavatum and scoliosis. Thoracic anomalies associated with pulmonary disease caused by M. avium complex. Am Rev Respir Dis 1991;144:914-916
37. Iseman MD. Mycobacterium avium complex and the normal host: the other side of the coin. N Engl J Med 1989;321:896-898
38. Prince DS, Peterson DD, Steiner RM, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989;321:863-868
39. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease: incidence, presentation, and response to therapy in a community setting. Am Rev Respir Dis 1991; 143:1381-1385
40. Kubo K, Yamazaki Y, Haciya T, et al. Pulmonary M. avium-intracellulare infection in patient without known predisposing lung disease. Lung 1998;176:381-389
41. Hawkins CC, Gold WM, Whimbey E, et al. M. avium complex infections in patients with aquired immunodeficiency syndrome. Ann Intern Med 1986;105:184-188
42. Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of M. avium-intracellulare complex in human immunodeficiency virus-positive patients. J Infect Dis 1992;165:1082-1085
43. Horsburgh CR. M. avium complex infection in the aquired immunodeficiency syndrome. N Engl J Med 1991;324:1332-1338
44. Sanchez T, Vanderkolk J, Seay S, Heifets L. Quantitation of mycobacteria in blood specimens from patients with AIDS. Tubercle and Lung Disease 1994;75:386-390
45. Heifets LB. Quantitative cultures and drug susceptibility testing of M. avium clinical isolates before and during the antimicrobial therapy (review). Res Microbiol 1994;145:188-196
46. Jones D, Havlir DV. Nontuberculouse mycobacteria in HIV infected patient. In: Catanzaro A, Daley CL, eds. Lung Disease Due to Nontuberculous Mycobacterial Infections. Philadelphia: WB Saunders; 2003:665-674 Clinics in Chest Medicine, Vol 23
47. Yates MD, Grange JM, Collins CH. The nature of mycobacterial disease in south-east England. J Epidemiol 1986; 40:295-300
48. Bittner MJ, Horowitz EA, Safranek TJ, Preheim LC. Emergence of M. kansasii as a leading mycobacterial pathogen isolated over a 20-year period at a midwestern Veterans Affairs hospital. Clin Infect Dis 1996;22:1109-1110
49. Griffith DE. Management of disease due to M. kansasii. In: Catanzaro A, Daley CL, eds. Lung Disease Due to Nontuberculous Mycobacterial Infections. Philadelphia: WB Saunders; 2003:613-625 Clinics in Chest Medicine, Vol 23
50. Byrd RP, Mirza S, Roy TM. Lady Windermere's syndrome: an atypical presentation of an atypical mycobacterium. J Tenn Med Assoc 1995;88:303-305
51. Dhillon SS, Watanakunakorn C. Lady Windermere Syndrome: middle lobe bronchiectasis and M.avium complex infection due to voluntary cough suppression. Clin Infect Dis 2000;30:572-575
52. Levin DL. Radiology of pulmonary M. avium-intracellulare complex. In: Catanzaro A, Daley CL, eds. Lung Disease Due to Nontuberculous Mycobacterial Infections. Philadelphia: WB Saunders; 2003:603-612 Clinics in Chest Medicine, Vol 23
53. Griffith DE, Girard WM, Wallace RJ. Clinical features of pulmonary disease caused by rapidly growing mycobacteria: an anlysis of 154 patiemts. Am Rev Respir Dis 1993;147:1271-1278
54. Daley CL, Griffith DE. Pulmonary disease caused by rapidly growing mycobacteria. In: Catanzaro A, Daley CL, eds. Lung Disease Due to Nontuberculous Mycobacterial Infections. Philadelphia: WB Saunders; 2003:623-632 Clinics in Chest Medicine, Vol 23
55. Johnston JM. Izumi AK Cutaneous M. marinum infection ("swimming pool granuloma"). Clin Dermatol 1988;5:68-75
56. Males BM, West TE, Bartolomew WR. M. haemophilum infection in a patient with aquired immunodeficiency syndrome. J Clin Microbiol 1987;25:186-190
57. Rogers PL, Walker RE, Lane HC, et al. Disseminated M. haemophilum infection in two patients with the aquired immunodeficiency syndrome. Am J Med 1988;84:640-642
58. Wallace RJ. The clinical presentation, diagnosis, and therapy of cutaneous and pulmonary infections due to the rapidly growing mycobacteria M. fortuitum and M. chelonae. Clin Chest Med 1989;10:419-429
59. Dautzenberg B, Truffot C, Legris S, et al. Activity of clarithromycin against M. avium infection in patients with aquired immunodeficiency syndrome. Am Rev Respir Dis 1991;144:564-569
60. Dautzenberg B, Saint Mark T, Meyohas MC, et al. Clarithromycin and other antimicrobial agents in the treatment of disseminated M. avium infections in patients with aquired immunodeficiency syndrome. Arch Intern Med 1993; 153:368-372
61. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic M. avium complex disease: a randomized double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994;121:905-911
62. Wallace RJ, Brown BA, Griffith DE, et al. Initial clarithromycin monotherapy for M. avium-intracellulare complex lung disease. Am J Respir Crit Care Med 1994;149:1335-1341
63. Dautzenberg B, Piperno D, Diot P, et al. Clarithromycin in the treatment of M. avium lung infections in patients without AIDS. Chest 1995;107:1035-1040
64. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as profilaxis against disseminated M. avium complex infection in patients with advanced aquired immunodeficiency syndrome. N Engl J Med 1996;355:384-391
65. Oldfield EC, Fessel WJ, Dunne MW, et al. Once weekly azithromycin therapy for prevention of M. avium infection in patients with AIDS: a randomized, double-blind, placebo-controlled multi-center trial. Clin Infect Dis 1998;26:611-619
66. Cohn DL, Fisher EJ, Peng GT, et al. A prospective randomized trial of four three-drug regimens in the treatment of disseminated M. avium complex disease in AIDS patients: excess mortality associated with high dose clarithromycin. Terry Beirn Community Programs for clinical research on AIDS. Clin Infect Dis 1999;29:125-133
67. Gordin FM, Sullam PM, Shafran SD, et al. A randomized, placebo-controlled study of rifabutin added to a regimen of darithromycin and ethambutol for treatment of disseminated infection with M. avium complex. Clin Infect Dis 1999;28: 1080-1085
68. Benson CA, Williams PL, Currier JC, et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for treatment of disseminated M. avium complex disease in persons with aquired immunodeficiency syndrome. Clin Infect Dis 2003;37:1234-1243
69. Chaison RE, Keiser P, Pierce M, et al. Clarithromycin and ethambutol with or without dofazimine for the treatment of bacteremic M. avium complex disease in patients with HIV infection. AIDS 1997;11:311-317
70. Ward TT, Rimland D, Kauffman C, Huycke M, Evans TG, Heifets L. Randomized, open-label trial of azithromycin plus ethambutol vs. darithromycin plus ethambutol as therapy for M. avium complex bacteremia in patients with human immunodeficiency virus infection. Clin Infect Dis 1998;27: 1278-1285
71. Wallace RJ, Brown BA, Griffith DE, et al. Clarithromycin regimens for pulmonary M. avium complex. Am J Respir Crit Care Med 1996;153:1766-1772
72. Griffith DE, Brown BA, Girard WM, et al. Azithromycin activity against M. avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin Infect Dis 1996;23:983-989
73. Dunne M, Fessel J, Kumar P, et al. A randomized, double-blind trial comparing azithromycyn and darithromycin in the treatment of disseminated M. avium infection in patients with human immunodeficiency virus. Clin Infect Dis 2000;31: 1245-1252
74. Iseman MD. Medical management of pulmonary disease caused by M, avium complex. In: Catanzaro A, Daley CL, eds. Lung Disease Due to Nontuberculous Mycobacterial Infections. Philadelphia: WB Saunders; 2003:633-641 Clinics in Chest Medicine, Vol 23
75. Heifets LB, Iseman MD. Choice of antimicrobial agents for M. avium disease based on quantitative tests of drug susceptibility. N Engl J Med 1990;323:419
76. Heifets LB, Iseman MD. Individualized therapy vs standard regimens in the therapy of M. avium infections [editorial]. Am Rev Respir Dis 1991;144:1-2
77. Heifets LB. Drug Susceptibility in the Chemotherapy of Mycobacterial Infections. Boca Raton: CRC; 1991
78. Heifets L. Susceptibility testing of M. avium complex isolates (review). Antimicrob Agents Chemother 1996;40:1759-1767
79. Heifets LB. Clarithromycin against M. avium complex infections (review). Tubercle and Lung Disease 1996;77:19-26
80. Siddiqi SH, Heifets LB, Cynamon MH, et al. Rapid broth macridilution method for determination of MICs for M. avium isolates. J Clin Microbiol 1993;31:2332-2338
81. Heifets L, Mor N, Vandercolk J. M. avium strains resistant to clarithromycin and azithromycin. Antimicrob Agents Chemother 1993;37:2364-2370
82. Craft JC, Notario GF, Grosset JH, Heifets LB. Clarithromycin resistance and susceptibility pattern in M. avium strains isolated during prophylaxis of disseminated infection in patients with AIDS. Clin Infect Dis 1998;2:430-434
83. Davidson P, Khanijo V, Goble M, et al. Treatment of disease due to M. intraacellulare. Rev Infect Dis 1981;3:1052-1059
84. Horsburgh CR, Mason UG, Heifets LB, et al. Response to therapy of pulmonary M. avium-intracellulare infection correlates with results of in vitro susceptibility testing. Am Rev Respir Dis 1987;135:418-421
85. Tsukamura M. Evidence that antituberculosis drugs are really effective in the treatment of pulmonary infection caused by M. avium complex. Am Rev Respir Dis 1988;137:144-148
86. Research Committee of the British Thoracic Society. First randomized trial on treatments for pulmonary disease caused by M. avium-intracellulare, M. malmoense, and M. xenopi in HIV-negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001; 56:167-172
87. Woods GL, Brown-Elliott BA, Desmond PE, et al. Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes: Approved Standard. NCLLS document M-24-A. Wayne, PA: National Committee for Clinical Laboratory Standards; 2003
88. Wallace RJ, Brown-Elliot BA, Ward SC, et al. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001;45:764-767
89. Wallace RJ, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW. Comparison of the in vitro activity of the glycyicycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycidine against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002;46: 3164-3167
90. Hadjiliadis D, Adlakha A, Prakash UB. Rapidly growing mycobacterial lung infection in association with esophageal disorders. Mayo Clin Proc 1999;74:744-745
91. Ebert DL, Oliver KN. Nontuberculous mycobacteria in cystic fibrosis. Infect Dis Clin North Am 2002;16:221-234